Navigation Links
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Date:7/23/2008

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication. Last year, SPI-1005, an oral capsule containing ebselen entered Phase II testing with the US Navy for the prevention and treatment of noise induced hearing loss.

Currently there are no FDA approved drugs for the prevention and treatment of drug induced hearing loss or ototoxicity. SPI hopes to address this unmet medical need with its first in class first in indication drug. Several different research groups have shown that chemotherapy treatment reduces glutathione peroxidase (GPx) activity in the mammalian inner ear resulting in hearing loss, tinnitus, vertigo and dizziness. GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. "A dose limiting side effect of platinum based chemotherapies are their devastating ototoxicity and neurotoxicity, and SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies," said VP Eric Lynch, PhD.

"Otoprotectants such as SPI-3005 have the potential to reduce and/or alleviate chemotherapy-induced ototoxicity, and clinical studies should be pursued," said Stephen Fausti, PhD, and Director of the National Center for Rehabilitative Auditory Research (NCRAR) at the Portland VA, Professor of Otolaryngology and Neurology at Oregon Health Sciences University
'/>"/>

SOURCE Sound Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
4. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 OncoSec Medical Inc. ("OncoSec") ... immunotherapies, today announced that CEO and President Punit Dhillon ... the Company,s listing to The Nasdaq Stock Market at 9:30 ... in New York City .   ... and stakeholders, we are honored to open the Nasdaq to ...
(Date:7/1/2015)... PISCATAWAY, New Jersey , July 1, 2015 ... Centre (CCDC) celebrates 50 years of the Cambridge ... the launch of new software in the CSD-System ... the world,s most comprehensive collection of crystal structure ... interaction analysis, geometry analysis, and support for tailored ...
(Date:6/30/2015)... SANTA MONICA, Calif. , June 30, 2015 /PRNewswire/ ... th consecutive year, is an event dedicated to ... on the hottest issues and topics affecting the industry ... designed to address the challenges and opportunities facing today,s ... For more information and to register for MEDevice San ...
Breaking Medicine Technology:OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3Scientific Symposium and New Software for Crystallographers and Scientists Worldwide to Celebrate 50 Years of the Cambridge Structural Database 2Scientific Symposium and New Software for Crystallographers and Scientists Worldwide to Celebrate 50 Years of the Cambridge Structural Database 3MEDevice San Diego 2015 Attracts High-Tech Medical Industry 2
... ARBOR, Mich., Aug. 6 Terumo Heart, Inc. ... Left Ventricular Assist,System (LVAS) took place on July ... Ann Arbor, Michigan. The surgery was performed by,Francis ... U.S. Pivotal Trial. DuraHeart is the world,s first ...
... held on Wednesday, August 6, 2008 at 8:00 ... ... Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety results from ... for the treatment of nasolabial folds, or wrinkles.,Each study, conducted under an ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5
(Date:7/1/2015)... Florida (PRWEB) , ... July 01, 2015 , ... Trevor ... University of South Florida and continued at USF earning a Master’s degree in Microbiology. ... an active member of the American Dental Association, the Florida Dental Association and the ...
(Date:7/1/2015)... ... July 01, 2015 , ... Boar’s Head Brand®, one of ... for Independence Day celebrations with new takes on classic dishes. From chicken salad ... for any summertime get together. , “Celebrating with family, friends, and great food ...
(Date:7/1/2015)... ... 01, 2015 , ... B. E. Smith, the only full-service leadership solutions firm ... nursing officer recruitment for Capital Health in Pennington, N.J. One of ... has recently placed more than 1,000 healthcare executives into organizations. , Capital Health ...
(Date:7/1/2015)... ... July 01, 2015 , ... Incentivizing the use of generic ... with discounts as much as 80% or 90% off the prices for the brand-name ... to act to mitigate the financial impact of these high-cost generic drugs. The July ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... philosophies and approaches to case management, placement, sober companionship and delivery to wilderness ... approaches to working with and transporting clients with anxiety, ADHD, autism spectrum disorders, ...
Breaking Medicine News(10 mins):Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2
... ANDERSON, S.C., Sept. 17 Doctors Care is,pleased to ... the,Upstate, located at 2126 Hwy 81 North, Anderson. The ... Parks, the Upstate Regional Medical Director for Doctors,Care stated, ... urgent care, family care, and occupational medicine, with or,without ...
... MORRISTOWN, N.J., Sept. 17 Actavis Group, ... Actavis,Elizabeth L.L.C. has initiated a challenge of ... Avinza(R) (morphine sulfate,extended-release capsules). Actavis believes that ... Abbreviated New Drug Application (ANDA) containing a ...
... CRH Medical Corporation,(CRM:TSX-V) announced today that due to ... Ronald Rosen as the second Physician in its ... the Company will continue,to increase the revenue of ... associated with a new site. CRH Medical ...
... Meritain Health to strengthen brand recognition, national ... and wellness products, BUFFALO, N.Y., Sept. 17 ... self-funded health plans, today announced,the name change of ... the single name of Meritain Health. Meritain ...
... treatment, researchers say , , MONDAY, Sept. 17 (HealthDay News) ... plays a crucial role in the ability of breast ... that transcription factor AP2C (TFAP2C) controls multiple pathways of ... breast cancer and may help explain differences in the ...
... from Columbia University Medical Center has received a $10.8 ... Institutes of Health to investigate why people with type ... leading cause of death for people suffering from diabetes. ... (Betsy) G. Nabel, M.D., director of The National Heart ...
Cached Medicine News:Health News:UCI Medical Affiliates Inc. Opens a New Doctors Care Center in Anderson 2Health News:Actavis Confirms its Patent Challenge of King's Avinza(R) 2Health News:CRH Medical expands Las Vegas operations 2Health News:Meritain Health Announces Name Change for Acquired Companies 2Health News:NIH awards $10.8M to Columbia to study connection between diabetes and heart disease 2Health News:NIH awards $10.8M to Columbia to study connection between diabetes and heart disease 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: